U.S. markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,850.60
    +3.00 (+0.16%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.01%)
     
  • BTC-USD

    28,937.56
    +306.84 (+1.07%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

Ryanair (RYAAY) Cuts Fiscal 2022 Guidance on Omicron-Led Woes

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Ryanair Holdings RYAAY has reduced its fiscal 2022 guidance as Omicron fears and travel restrictions across Europe have weakened close-in Christmas & New Year bookings.

RYAAY now anticipates fiscal 2022 traffic to be little less than 100 million passengers compared with the previous expectation of just above 100 million. Net loss is expected to be in the range of €250-€450 million compared with the previously guided range of €100-€200 million.

Ryanair has lowered its December traffic forecast to 9-9.5 million passengers from 10-11 million expected earlier. The traffic forecast has been lowered due to the effects of government travel restrictions, especially France and Germany’s ban on UK travelers and the suspension of EU flights to/from Morocco. The airline has slashed its planned January schedule capacity by 33%. It now expects January traffic to be 6-7 million from 10 million expected previously. RYAAY is yet to decide on schedule cutbacks for February and March 2022.

Ryanair Holdings PLC Price

Ryanair Holdings PLC Price
Ryanair Holdings PLC Price

Ryanair Holdings PLC price | Ryanair Holdings PLC Quote

Zacks Rank & Key Picks

Ryanair carries a Zacks Rank #4 (Sell).

Here are some better-ranked stocks within the broader Transportation sector:

ArcBest Corporation ARCB flaunts a Zacks Rank #1 (Strong Buy). The company has a stellar earnings surprise history. It has outperformed the Zacks Consensus Estimate for earnings in each of the preceding four quarters, the average surprise being 27.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of ArcBest have surged more than 100% so far this year.

Expeditors International of Washington EXPD carries a Zacks Rank #1. The company’s earnings have outperformed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 29.1%.

Shares of Expeditors have appreciated more than 36% so far this year.

Schneider National SNDR carries a Zacks Rank #1. The company’s earnings have trumped the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 21%.

Shares of Schneider National have rallied more than 25% so far this year.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ryanair Holdings PLC (RYAAY) : Free Stock Analysis Report

Expeditors International of Washington, Inc. (EXPD) : Free Stock Analysis Report

ArcBest Corporation (ARCB) : Free Stock Analysis Report

Schneider National, Inc. (SNDR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research